Review of NICE Technology Appraisal Guidance No 96, on the use of adefovir dipivoxil and peginterferon alfa-2a for the treatment of chronic hepatitis B
Proposal to defer the review

Following a search for information relevant to this appraisal and the recent referral of the Single Technology Appraisals for entecavir for (chronic) hepatitis B and telbivudine for (chronic) hepatitis B the Institute proposes that the decision to review the original guidance is deferred until February 2009. At this point we are likely to know the outcome of the appraisals of entecavir and telbivudine. We will then look again at the evidence base to ascertain the need for a review of the guidance.

In order to be completely confident that this is appropriate, we are asking all relevant consultees and commentators, to inform us of any evidence which would suggest that a review would be beneficial.  Please see Appendix A for a full list of the organisations we have contacted. 

Please note all comments received will be published on the Institute’s website when a decision has been taken. 

24 July 2007